Application notesIs unsuitable for Flow Cyt or IHC-P.
FunctionMetalloprotease that specifically cleaves 'Lys-63'-linked polyubiquitin chains (PubMed:19214193, PubMed:20656690, PubMed:24075985, PubMed:26344097). Does not have activity toward 'Lys-48'-linked polyubiquitin chains. Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). In the BRCA1-A complex, it specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX, antagonizing the RNF8-dependent ubiquitination at double-strand breaks (DSBs) (PubMed:20656690). Catalytic subunit of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin in various substrates (PubMed:20656690, PubMed:24075985, PubMed:26344097, PubMed:26195665). Mediates the specific 'Lys-63'-specific deubiquitination associated with the COP9 signalosome complex (CSN), via the interaction of the BRISC complex with the CSN complex (PubMed:19214193). The BRISC complex is required for normal mitotic spindle assembly and microtubule attachment to kinetochores via its role in deubiquitinating NUMA1 (PubMed:26195665). Plays a role in interferon signaling via its role in the deubiquitination of the interferon receptor IFNAR1; deubiquitination increases IFNAR1 activity by enhancing its stability and cell surface expression (PubMed:24075985, PubMed:26344097). Down-regulates the response to bacterial lipopolysaccharide (LPS) via its role in IFNAR1 deubiquitination (PubMed:24075985).
Tissue specificityHeart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Aberrantly expressed in the vast majority of breast tumors.
Involvement in diseaseA chromosomal aberration involving BRCC3 is a cause of pro-lymphocytic T-cell leukemia (T-PLL). Translocation t(X;14)(q28;q11) with TCRA.
Sequence similaritiesBelongs to the peptidase M67A family. BRCC36 subfamily. Contains 1 MPN (JAB/Mov34) domain.
Cellular localizationNucleus. Cytoplasm. Cytoplasm, cytoskeleton, spindle pole. Localizes at sites of DNA damage at double-strand breaks (DSBs) (PubMed:20656690, PubMed:26344097). Interaction with FAM175B/ABRO1 retains BRCC3 in the cytoplasm (PubMed:20656690).
Western blot - Anti-BRCC36 antibody [EPR4365] (ab108295)
Predicted band size : 36 kDa
Lane 1: Wild type HAP1 whole cell lysate (40 µg) Lane 2: Empty Lane Lane 3: BRCC36 knockout HAP1 whole cell lysate (40 µg) Lane 4: MCF7 whole cell lysate (40 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab108295 observed at 36 kDa. Red - loading control, ab18058, observed at 130 kDa.
ab108295 was shown to recognize empty when empty knockout samples were used, along with additional cross-reactive bands. Wild-type and empty knockout samples were subjected to SDS-PAGE. Ab108295 and ab18058 (Mouse anti Vinculin loading control) were incubated overnight at 4°C at 1000 dilution and 1/10000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.
Western blot - BRCC36 antibody [EPR4365] (ab108295)
All lanes : Anti-BRCC36 antibody [EPR4365] (ab108295) at 1/1000 dilution
Lane 1 : MCF7 cell lysate Lane 2 : SKBR3 cell lysate Lane 3 : 293T cell lysate Lane 4 : Human fetal kidney lysate Lane 5 : HeLa cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size : 36 kDa
References for Anti-BRCC36 antibody [EPR4365] (ab108295)
has not yet been referenced specifically in any publications.
Publishing research using ab108295? Please let us know so that we can cite the reference in this datasheet.
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"